Lv1
30 积分 2025-08-21 加入
Exposure-Response Of Idelalisib, a Novel PI3Kδ Inhibitor, Administered As Monotherapy In The Treatment Of Hematologic Malignancies
1天前
求助中
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
1天前
已完结
Cutting Edge: The Phosphoinositide 3-Kinase p110δ Is Critical for the Function of CD4+CD25+Foxp3+ Regulatory T Cells
2天前
已完结
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
2天前
已完结
The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
1个月前
已完结
Functional Peptides in Targeted Cancer Therapy: Mechanisms, Delivery Strategies, and Clinical Perspectives
1个月前
已完结
PIK3CAH1047R induces multipotency and multi-lineage mammary tumours
2个月前
已完结
Phosphatidylinositol 3-kinase mediates proliferative signals in intestinal epithelial cells
2个月前
已完结
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study
3个月前
已完结
BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction
6个月前
已完结
皖公网安备34019202002308
